Fundraising FoxAmpel
Charlottesville, US · Virginia LLC
Find your way into Ampel
Sign up to see every warm intro you have to Ampel
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ampel team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AMPEL BioSolutions develops RNA-based precision medicine products using its AMPEL Genomic Platform (AGP), which combines RNA analytics and predictive AI to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets from blood and biopsy tests. Its clinical products, such as LuGENE, DermaGENE, and WellGENE, support genomic diagnostics for patient disease management.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 5 rounds · 2019–2023
▶$1.8MraisedJul 2023 · 5 investors · BiotechnologyRule 506(b)
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1.8M
- Minimum investment
- $100K
- First sale
- Apr 2023
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$1.1MraisedDec 2022 · 3 investors · BiotechnologyRule 506(b)
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $100K
- First sale
- Nov 2022
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$350KraisedJun 2021 · 2 investors · BiotechnologyRule 506(b)
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $5M
- Amount sold
- $350K
- Minimum investment
- $100K
- First sale
- May 2021
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$500KraisedFeb 2021 · 1 investors · BiotechnologyRule 506(b)
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $150K
- First sale
- Nov 2019
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
▶$1MraisedJan 2021 · 5 investors · BiotechnologyRule 506(b)
- Peter LipskyExecutive Officer
- Amrie GrammerExecutive Officer
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $100K
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Virginia
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Ampel.
Frequently asked questions
- What does Ampel do?
- AMPEL BioSolutions develops RNA-based precision medicine products using its AMPEL Genomic Platform (AGP), which combines RNA analytics and predictive AI to evaluate disease status, identify cellular functions and pathways, and predict disease flares and drug targets from blood and biopsy tests. Its clinical products, such as LuGENE, DermaGENE, and WellGENE, support genomic diagnostics for patient disease management.
- Who founded Ampel?
- Ampel was founded by Peter Lipsky, Amrie Grammer.
- How much funding has Ampel raised?
- Ampel has disclosed $4.8M raised across 5 rounds.
- Where is Ampel headquartered?
- Ampel is headquartered in Charlottesville, US.